ArchivesMagazine - 05 Feb 2015Angle enters new phase Research sales imminent while ovarian cancer test trials commence 05 February 2015|News|by Mark Dunne Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Deal elevates CRH Payrolls next test for S&P > Issue: 05 Feb 2015 - Page 12 | Contents Next: Payrolls next test for S&P Previous: Deal elevates CRH Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Mark Dunne Issue Contents Chartist Consumer product rally Feature All eyes on pension deficits Preview: Lancashire Securing the web: The best ways to play cyber security Director dealings: Top buys & Sells ASOS back in fashion What Woodford is buying Staffline gets to work Best & Worst Small Cap Performing Tables Climb with Fever-Tree Essential Guide to AIM Stocks: ‘R’ to ‘Z’ Gold’s currency dims The property guy The Best & Worst Performers: FTSE 350, Global Market, Commodities, Forex, Sovereign Yields Fight For Your Rights Asking the right questions News Look to the future with Flow Cosy up to ScS Deal elevates CRH Payrolls next test for S&P News in brief: Eclectic Bar, Royal Dutch Shell, Domaine Chanzy, ITV, M&B, Braemar, Ideagen, Creston, Air Partner, Scotgold revival Angle enters new phase Rank’s digital success Plays Avoid a losing GAME InternetQ dials up growth Plays update: Ashcourt Rowan Plays update: ISG 15 for 15 update: Gamma Communications 15 for 15 update: ClearStar Trading Strategies Platform for profits Under The Bonnet Utilitywise to rise above doubts
